The Cancer Letter

Inside information on cancer research and drug development

In Brief

Experimental Therapeutics at Mount Sinai team up with Regeneron on antibody research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THE EXPERIMENTAL THERAPEUTICS INSTITUTE at the Icahn School of Medicine at Mount Sinai and Regeneron Pharmaceuticals Inc. entered into an agreement with the goal of accelerating the discovery of fully-human antibodies directed against therapeutic targets being researched by Mount Sinai investigators.

Regeneron will provide the ETI with access to VelocImmune technology and potential financial support to use the company’s proprietary antibody discovery platform to generate antibodies against targets of interest and explore potential therapeutic applications for human disease.

ETI will undertake preclinical research and Regeneron has an exclusive option to negotiate a license to the antibody for future clinical development and commercialization.

Developed by Regeneron scientists, VelocImmune is a genetic engineering platform that enables the fast and efficient creation of superior fully-human monoclonal antibodies for drug development.

Table of Contents

YOU MAY BE INTERESTED IN

White House

Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future

The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and his crew have “flooded the zone”—the term and the image are theirs, as is the strategy of dropping a flurry of executive orders and memoranda that shake the foundations of the American system of government, raising questions of legality and constitutionality, and, above all, making it a challenge for anyone to see the entire picture and think strategically.
By Paul Goldberg
Capitol Hill

With a spotlight on vaccines, abortion, Medicaid and Medicare, RFK Jr. goes before the Senate
The MAHA nominee trumpets radical transparency, but offers little clarity on his new agenda

In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services. 
By Claire Marie Porter
Guest Editorial

Cancer research fuels life-saving work

Over the past century, groundbreaking cancer research in the U.S. has led to life-saving medical advances that benefit patients worldwide. Scientists often devote their lives to making discoveries, putting their scientific endeavors ahead of status, income, or lifestyle. Investigators work tirelessly, often seven days a week, to solve complex medical problems. These efforts often lead to game-changing outcomes that help us understand difficult medical challenges, advance technologies and develop new therapies. 
By Ze’ev Ronai
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account